Table 3 Characteristics of muscle samples from the patient cohort used in this study (n = 35). The table displays the differences between the muscle samples that were considered in the analysis to reduce the effect of technical variability.
Sample | Group | Cartridge | Field-of-view (FOV) | Conservation method |
|---|---|---|---|---|
1 | NDC | C12 | 555 | FFPE |
2 | NDC | C12 | 555 | FFPE |
3 | NDC | C12 | 555 | Cryopreserved |
4 | NDC | C12 | 555 | Cryopreserved |
5 | Mi2 subtype | C49 | 194 | Cryopreserved |
6 | Mi2 subtype | C49 | 194 | Cryopreserved |
7 | Mi2 subtype | C15 | 555 | Cryopreserved |
8 | Mi2 subtype | C15 | 555 | Cryopreserved |
9 | Mi2 subtype | C15 | 555 | Cryopreserved |
10 | Mi2 subtype | C15 | 555 | Cryopreserved |
11 | Mi2 subtype | C15 | 555 | Cryopreserved |
12 | Mi2 subtype | C15 | 555 | Cryopreserved |
13 | TIF1γ subtype | C15 | 555 | Cryopreserved |
14 | TIF1γ subtype | C15 | 555 | Cryopreserved |
15 | TIF1γ subtype | C15 | 555 | Cryopreserved |
16 | TIF1γ subtype | C15 | 555 | Cryopreserved |
17 | TIF1γ subtype | C19 | 555 | Cryopreserved |
18 | TIF1γ subtype | C20 | 555 | Cryopreserved |
19.1 | irMyositis | C15 | 555 | Cryopreserved |
19.2 | irMyositis | C49 | 194 | Cryopreserved |
20 | irMyositis | C12 | 555 | FFPE |
21 | irMyositis | C12 | 555 | FFPE |
22 | irMyositis | C12 | 555 | FFPE |
23.1 | irMyositis | C14 | 555 | FFPE |
23.2 | irMyositis | C12 | 555 | FFPE |
24 | irMyositis | C20 | 555 | Cryopreserved |
25 | irMyositis | C20 | 555 | Cryopreserved |
26 | irMyositis | C20 | 555 | Cryopreserved |
27 | irMyositis | C20 | 555 | Cryopreserved |
28 | irMyositis | C20 | 555 | Cryopreserved |
29 | irMyositis | C20 | 555 | Cryopreserved |
30 | irMyositis | C19 | 555 | Cryopreserved |
31 | irMyositis | C48 | 555 | Cryopreserved |
32 | irMyositis | C48 | 555 | Cryopreserved |
33 | irMyositis | C49 | 194 | Cryopreserved |
